S&P 500   3,293.21 (-0.04%)
DOW   26,635.84 (-0.11%)
QQQ   269.95 (+0.21%)
AAPL   438.96 (+0.74%)
MSFT   213.30 (-1.50%)
FB   251.04 (-0.37%)
GOOGL   1,483.22 (+0.03%)
AMZN   3,150.50 (+1.24%)
NVDA   442.56 (+0.49%)
CGC   18.80 (-1.36%)
BABA   260.00 (+0.80%)
TSLA   1,523.00 (+2.56%)
MU   51.19 (+1.59%)
GE   6.15 (+0.65%)
AMD   81.94 (+5.50%)
F   6.88 (+2.84%)
ACB   10.29 (-1.25%)
GILD   71.35 (-0.53%)
NFLX   506.55 (+1.59%)
DIS   116.53 (+0.15%)
BAC   24.99 (-0.08%)
S&P 500   3,293.21 (-0.04%)
DOW   26,635.84 (-0.11%)
QQQ   269.95 (+0.21%)
AAPL   438.96 (+0.74%)
MSFT   213.30 (-1.50%)
FB   251.04 (-0.37%)
GOOGL   1,483.22 (+0.03%)
AMZN   3,150.50 (+1.24%)
NVDA   442.56 (+0.49%)
CGC   18.80 (-1.36%)
BABA   260.00 (+0.80%)
TSLA   1,523.00 (+2.56%)
MU   51.19 (+1.59%)
GE   6.15 (+0.65%)
AMD   81.94 (+5.50%)
F   6.88 (+2.84%)
ACB   10.29 (-1.25%)
GILD   71.35 (-0.53%)
NFLX   506.55 (+1.59%)
DIS   116.53 (+0.15%)
BAC   24.99 (-0.08%)
S&P 500   3,293.21 (-0.04%)
DOW   26,635.84 (-0.11%)
QQQ   269.95 (+0.21%)
AAPL   438.96 (+0.74%)
MSFT   213.30 (-1.50%)
FB   251.04 (-0.37%)
GOOGL   1,483.22 (+0.03%)
AMZN   3,150.50 (+1.24%)
NVDA   442.56 (+0.49%)
CGC   18.80 (-1.36%)
BABA   260.00 (+0.80%)
TSLA   1,523.00 (+2.56%)
MU   51.19 (+1.59%)
GE   6.15 (+0.65%)
AMD   81.94 (+5.50%)
F   6.88 (+2.84%)
ACB   10.29 (-1.25%)
GILD   71.35 (-0.53%)
NFLX   506.55 (+1.59%)
DIS   116.53 (+0.15%)
BAC   24.99 (-0.08%)
S&P 500   3,293.21 (-0.04%)
DOW   26,635.84 (-0.11%)
QQQ   269.95 (+0.21%)
AAPL   438.96 (+0.74%)
MSFT   213.30 (-1.50%)
FB   251.04 (-0.37%)
GOOGL   1,483.22 (+0.03%)
AMZN   3,150.50 (+1.24%)
NVDA   442.56 (+0.49%)
CGC   18.80 (-1.36%)
BABA   260.00 (+0.80%)
TSLA   1,523.00 (+2.56%)
MU   51.19 (+1.59%)
GE   6.15 (+0.65%)
AMD   81.94 (+5.50%)
F   6.88 (+2.84%)
ACB   10.29 (-1.25%)
GILD   71.35 (-0.53%)
NFLX   506.55 (+1.59%)
DIS   116.53 (+0.15%)
BAC   24.99 (-0.08%)
Log in

NASDAQ:BEATBioTelemetry Stock Price, Forecast & News

$42.86
+0.30 (+0.70 %)
(As of 08/4/2020 09:37 AM ET)
Add
Compare
Today's Range
$42.51
Now: $42.86
$44.35
50-Day Range
$39.39
MA: $43.33
$48.37
52-Week Range
$27.35
Now: $42.86
$55.85
Volume411,614 shs
Average Volume421,658 shs
Market Capitalization$1.46 billion
P/E Ratio82.42
Dividend YieldN/A
Beta1.21
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and INR monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Corporate and Other segment focuses on the manufacture, engineering, development, and sale of non-invasive cardiac monitors and other population health management devices for healthcare companies, as well as contract manufacturing services under the BioTel Care and BioTel Alliance names. The company was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Read More
BioTelemetry logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BEAT
CUSIPN/A
Phone610-729-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$439.11 million
Cash Flow$3.39 per share
Book Value$10.83 per share

Profitability

Net Income$29.84 million

Miscellaneous

Employees1,700
Market Cap$1.46 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$42.86
+0.30 (+0.70 %)
(As of 08/4/2020 09:37 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

How has BioTelemetry's stock been impacted by COVID-19 (Coronavirus)?

BioTelemetry's stock was trading at $37.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BEAT stock has increased by 14.1% and is now trading at $42.86.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of BioTelemetry?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioTelemetry
.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for BioTelemetry
.

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) released its quarterly earnings data on Thursday, July, 30th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.16 by $0.19. The medical research company had revenue of $99.11 million for the quarter, compared to the consensus estimate of $85.93 million. BioTelemetry had a net margin of 4.42% and a return on equity of 17.68%.
View BioTelemetry's earnings history
.

What price target have analysts set for BEAT?

4 analysts have issued 1 year target prices for BioTelemetry's shares. Their forecasts range from $55.00 to $80.00. On average, they anticipate BioTelemetry's share price to reach $67.00 in the next twelve months. This suggests a possible upside of 56.3% from the stock's current price.
View analysts' price targets for BioTelemetry
.

Has BioTelemetry been receiving favorable news coverage?

News coverage about BEAT stock has been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioTelemetry earned a coverage optimism score of -1.7 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about BioTelemetry
.

Are investors shorting BioTelemetry?

BioTelemetry saw a increase in short interest in July. As of July 15th, there was short interest totaling 2,980,000 shares, an increase of 13.7% from the June 30th total of 2,620,000 shares. Based on an average trading volume of 322,100 shares, the short-interest ratio is presently 9.3 days. Approximately 9.0% of the shares of the company are short sold.
View BioTelemetry's Current Options Chain
.

Who are some of BioTelemetry's key competitors?

Some companies that are related to BioTelemetry include Acadia Healthcare (ACHC), Hanger (HNGR), Biocorrx (BICX), IMAC (IMAC) and AAC (AAC).
View all competitors
.

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Netflix (NFLX), Square (SQ), ABIOMED (ABMD), Canopy Growth (CGC), Paypal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Adobe (ADBE).

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the following people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 44)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)
  • Mr. Daniel M. Wisniewski, Sr. VP of Technical Operations (Age 55)

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by many different retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (1.07%), Vident Investment Advisory LLC (0.76%), Vident Investment Advisory LLC (0.76%), Ziegler Capital Management LLC (0.74%), Pembroke Management LTD (0.62%) and Scout Investments Inc. (0.52%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, Heather C Getz, Kirk E Gorman, Peter Ferola and Robert J Rubin.
View institutional ownership trends for BioTelemetry
.

Which major investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, SG Americas Securities LLC, Raymond James & Associates, Raymond James Financial Services Advisors Inc., Envestnet Asset Management Inc., Scout Investments Inc., Mesirow Financial Investment Management Inc., and Foundry Partners LLC.
View insider buying and selling activity for BioTelemetry
.

Which major investors are buying BioTelemetry stock?

BEAT stock was acquired by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Cadence Capital Management LLC, Strs Ohio, Tealwood Asset Management Inc., Ziegler Capital Management LLC, Pembroke Management LTD, Vident Investment Advisory LLC, and Vident Investment Advisory LLC.
View insider buying and selling activity for BioTelemetry
.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $42.86.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.46 billion and generates $439.11 million in revenue each year. The medical research company earns $29.84 million in net income (profit) each year or $1.95 on an earnings per share basis. BioTelemetry employs 1,700 workers across the globe.

What is BioTelemetry's official website?

The official website for BioTelemetry is www.gobio.com.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.